@article{oai:nagasaki-u.repo.nii.ac.jp:00001362,
 author = {Horie, Ichiro and Haraguchi, Ai and Sako, Ayaka and Akeshima, Junya and Niri, Tetsuro and Shigeno, Riyoko and Ito, Ayako and Nozaki, Aya and Natsuda, Shoko and Akazawa, Satoru and Mori, Yoshitaka and Ando, Takao and Kawakami, Atsushi and Abiru, Norio},
 journal = {Diabetes Research and Clinical Practice},
 month = {Oct},
 note = {Aims: To evaluate the glycaemic control of combination therapy with basal insulin and liraglutide, and to explore the factors predictive of efficacy in patients with type 2 diabetes when switched from longstanding basal-bolus insulin therapy. Methods: We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy. Glycaemic control was evaluated at 6 months after switching therapy and used to subdivide the patients into good-responders (HbA1c <7.0% or 1.0% decrease) and poor-responders (the rest of participants). To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration. Results: Twenty-eight patients (68.3%) were identified as good-responders. No differences were found in baseline characteristics including insulin/glucagon responses during 1st-OGTT between the groups. 2nd-OGTT revealed that paradoxical hyperglucagonemia were significantly improved in both groups, but significant increases in insulin secretory response were observed only in good-responders. Logistic regression analyses revealed that the improvement of the insulin-response during 2nd-OGTT compared to that during 1st-OGTT is associated with the good-responder. Conclusions: Enhancement of glucose-dependent insulin-response under liraglutide administration is a potential predictor of long-term glycaemic control after switching the therapies., Diabetes Research and Clinical Practice, 144, pp.161-170; 2018},
 pages = {161--170},
 title = {Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6?months after switching therapy},
 volume = {144},
 year = {2018}
}